Baxano Surgical Stock Price, News & Analysis (OTCMKTS:BAXSQ)

$0.0040 0.00 (0.00 %)
(As of 03/19/2018 04:00 PM ET)
Previous Close$0.00
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market Capitalization$149,180.00
P/E Ratio-0.01
Dividend YieldN/A

About Baxano Surgical (OTCMKTS:BAXSQ)

Baxano Surgical logoBaxano Surgical, Inc., formerly Baxano Inc. is a medical device company. The Company is focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region. The Company markets the AxiaLIF pre-sacral access and interbody fusion system for single and two level lower lumbar fusion, the VEO lateral access and interbody fusion system, the iO-Flex set of flexible instruments used by surgeons during spinal decompression procedures, and the iO-Tome instrument for rapid and precise removal of bone, specifically the facet joints, a technique which is commonly performed in spinal fusion procedures. The Company's other products include: Vectre facet screw system, Bi-Ostetic bone void filler, bowel retractors, discectomy tools, and a bone graft harvesting system that can be used to extract bone graft from the patient's hip for use in fusion procedures.

Receive BAXSQ News and Ratings via Email

Sign-up to receive the latest news and ratings for BAXSQ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E Ratio-0.00588235294117647
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPS($0.68)
Net IncomeN/A
Net Margins-126.01%
Return on Equity-117.23%
Return on Assets-56.63%


Outstanding SharesN/A

Baxano Surgical (OTCMKTS:BAXSQ) Frequently Asked Questions

What is Baxano Surgical's stock symbol?

Baxano Surgical trades on the OTCMKTS under the ticker symbol "BAXSQ."

How were Baxano Surgical's earnings last quarter?

Baxano Surgical Inc (OTCMKTS:BAXSQ) issued its quarterly earnings results on Tuesday, August, 5th. The medical device company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.04. The medical device company had revenue of $4.66 million for the quarter, compared to the consensus estimate of $5.33 million. Baxano Surgical had a negative net margin of 126.01% and a negative return on equity of 117.23%. View Baxano Surgical's Earnings History.

Who are some of Baxano Surgical's key competitors?

Has Baxano Surgical been receiving favorable news coverage?

News headlines about BAXSQ stock have trended positive this week, according to Accern. The research group scores the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Baxano Surgical earned a media sentiment score of 0.30 on Accern's scale. They also assigned news stories about the medical device company an impact score of 46.96 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Baxano Surgical?

Shares of BAXSQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Baxano Surgical's stock price today?

One share of BAXSQ stock can currently be purchased for approximately $0.00.

How big of a company is Baxano Surgical?

Baxano Surgical has a market capitalization of $149,180.00.

How can I contact Baxano Surgical?

Baxano Surgical's mailing address is 110 Horizon Dr Ste 230, RALEIGH, NC 27615-4927, United States. The medical device company can be reached via phone at +1-919-8000020.

MarketBeat Community Rating for Baxano Surgical (BAXSQ)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  70 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  119
MarketBeat's community ratings are surveys of what our community members think about Baxano Surgical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Baxano Surgical (OTCMKTS:BAXSQ) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Baxano Surgical (OTCMKTS:BAXSQ) Earnings History and Estimates Chart

Earnings by Quarter for Baxano Surgical (OTCMKTS:BAXSQ)

Baxano Surgical (OTCMKTS BAXSQ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/5/2014($0.14)($0.18)$5.33 million$4.66 millionViewN/AView Earnings Details
5/8/2014($0.12)($0.19)$4.75 million$4.41 millionViewN/AView Earnings Details
3/6/2014($0.14)($0.19)$5.96 millionViewN/AView Earnings Details
11/6/2013Q3 2013($0.17)($0.17)$6.00 million$5.65 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.14)($0.21)$6.90 million$3.90 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.22)($0.21)$3.20 million$3.10 millionViewN/AView Earnings Details
3/4/2013Q4 2012($0.20)($0.20)$3.82 million$4.10 millionViewN/AView Earnings Details
11/8/2012Q312($0.16)($0.22)$4.70 million$3.20 millionViewN/AView Earnings Details
8/9/2012Q2 2012($0.20)($0.23)ViewN/AView Earnings Details
5/8/2012Q1 2012($0.17)($0.21)ViewN/AView Earnings Details
3/8/2012Q4 2011($0.13)($0.18)ViewN/AView Earnings Details
11/1/2011Q3 2011($0.22)($0.15)ViewN/AView Earnings Details
8/9/2011Q2 2011($0.22)($0.20)ViewN/AView Earnings Details
5/12/2011Q1 2011($0.23)($0.26)ViewN/AView Earnings Details
2/22/2011Q4 2010($0.18)($0.22)ViewN/AView Earnings Details
11/9/2010Q3 2010($0.24)($0.18)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.27)($0.16)ViewN/AView Earnings Details
5/4/2010Q1 2010($0.25)($0.25)ViewN/AView Earnings Details
2/23/2010Q4 2009($0.34)($0.28)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.35)($0.27)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.36)($0.33)ViewN/AView Earnings Details
4/27/2009Q1 2009($0.34)($0.25)ViewN/AView Earnings Details
2/23/2009Q4 2008($0.25)($0.22)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.26)($0.23)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.21)($0.26)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.22)($0.12)ViewN/AView Earnings Details
2/21/2008Q4 2007($0.11)($0.14)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Baxano Surgical (OTCMKTS:BAXSQ) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Baxano Surgical (OTCMKTS:BAXSQ)

No dividend announcements for this company have been tracked by

Insider Trades

Baxano Surgical (OTCMKTS BAXSQ) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Baxano Surgical (OTCMKTS:BAXSQ)

Baxano Surgical (OTCMKTS BAXSQ) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/15/2014Kenneth Michael RealiCEOBuy10,000$0.38$3,800.00View SEC Filing  
5/12/2014Kenneth Michael RealiCEOBuy7,050$0.71$5,005.50View SEC Filing  
12/5/2013Kenneth Michael RealiCEOBuy10,500$1.11$11,655.00View SEC Filing  
5/31/2013Roderick A YoungDirectorBuy1,340,034$2.28$3,055,277.52View SEC Filing  
(Data available from 1/1/2013 forward)


Baxano Surgical (OTCMKTS BAXSQ) News Headlines

No headlines for this company have been tracked by

SEC Filings

Baxano Surgical (OTCMKTS:BAXSQ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Baxano Surgical (OTCMKTS BAXSQ) Stock Chart for Monday, March, 19, 2018

Loading chart…

This page was last updated on 3/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.